BioModelsapplication/xmlhttps://www.ebi.ac.uk/biomodels/model/download/BIOMD0000000743?filename=curation_notes.txthttps://www.ebi.ac.uk/biomodels/model/download/BIOMD0000000743?filename=Gallaher2018-biopax2.owlhttps://www.ebi.ac.uk/biomodels/model/download/BIOMD0000000743?filename=Gallaher2018-biopax3.owlhttps://www.ebi.ac.uk/biomodels/model/download/BIOMD0000000743?filename=Gallaher2018.xmlhttps://www.ebi.ac.uk/biomodels/model/download/BIOMD0000000743?filename=manifest.xmlhttps://www.ebi.ac.uk/biomodels/model/download/BIOMD0000000743?filename=Gallaher2018.sedmlhttps://www.ebi.ac.uk/biomodels/model/download/BIOMD0000000743?filename=Gallaher2018.cpshttps://www.ebi.ac.uk/biomodels/model/download/BIOMD0000000743?filename=Gallaher2018.odehttps://www.ebi.ac.uk/biomodels/model/download/BIOMD0000000743?filename=Gallaher2018-matlab.mhttps://www.ebi.ac.uk/biomodels/model/download/BIOMD0000000743?filename=curation_image.pnghttps://www.ebi.ac.uk/biomodels/model/download/BIOMD0000000743?filename=metadata.rdfhttps://www.ebi.ac.uk/biomodels/model/download/BIOMD0000000743?filename=Gallaher2018-octave.mprimary200OKJinghao MenManually curatedordinary differential equation modelL3V1Immuno-oncologyhttps://www.ebi.ac.uk/biomodels/BIOMD0000000743falseBioModelsModelsSBMLGallaher2018 Tumor–Immune dynamics in multiple myeloma2018MODEL1907050001Jill GallaherJill Gallaher, Kamila Larripa, Marissa Renardy, Blerta Shtylla, Nessy Tania, Diana White, Karen Wood, Li Zhu, Chaitali Passey, Michael Robbins, Natalie Bezman, Suresh Shelat, Hearn Jay Cho, Helen Moore10.1016/j.jtbi.2018.08.037, In this work, we analyze a mathematical model we introduced previously for the dynamics of multiple myeloma and the immune system. We focus on four main aspects: (1) obtaining and justifying ranges and values for all parameters in the model; (2) determining a subset of parameters to which the model is most sensitive; (3) determining which parameters in this subset can be uniquely estimated given cer- tain types of data; and (4) exploring the model numerically. Using global sensitivity analysis techniques, we found that the model is most sensitive to certain growth, loss, and efficacy parameters. This anal- ysis provides the foundation for a future application of the model: prediction of optimal combination regimens in patients with multiple myeloma.. null, 458. Helen Moore E-mail address: dr.helen.moore@gmail.com Current affiliation: AstraZeneca, Waltham, MA 02451, USAjm2187@cam.ac.uk10.1016/j.jtbi.2018.08.037University of CambridgeBIOMD0000000743In this work, we analyze a mathematical model we introduced previously for the dynamics of multiple myeloma and the immune system. We focus on four main aspects: (1) obtaining and justifying ranges and values for all parameters in the model; (2) determining a subset of parameters to which the model is most sensitive; (3) determining which parameters in this subset can be uniquely estimated given certain types of data; and (4) exploring the model numerically. Using global sensitivity analysis techniques, we found that the model is most sensitive to certain growth, loss, and efficacy parameters. This analysis provides the foundation for a future application of the model: prediction of optimal combination regimens in patients with multiple myeloma.Methods for determining key components in a mathematical model for tumor-immune dynamics in multiple myeloma.Gallaher Jill J, Larripa Kamila K, Renardy Marissa M, Shtylla Blerta B, Tania Nessy N, White Diana D, Wood Karen K, Zhu Li L, Passey Chaitali C, Robbins Michael M, Bezman Natalie N, Shelat Suresh S, Jay Cho Hearn H, Moore Helen HPlasma-Cell Myelomas, Plasmacytic myeloma, systemic, Plasma-cell myeloma, Plasma, amyloidosis, Disease, no ICD-O subtype (morphologic abnormality)., Multiple myeloma, Myelomas, Myeloma, Multiple myeloma (disorder), Kahler's disease, Cell Myelomas, Plasma Cell Myelomas, myeloma, Kahler Disease, Myeloma Multiple, Myeloma-Multiples, Myeloma-Multiple, Multiple myeloma without mention of remission, Multiple Myeloma, MM, Al amyloidosis, multiple myeloma, Multiple, Kahler, Multiple Myelomas, no ICD-O subtype, Cell Myeloma, multiple, Plasma Cell Myeloma, [M]Plasma cell myeloma, Myelomatoses, NOS, Myelomatosis, Multiple myeloma (clinical), Plasma Cell, MULT MYELM W/O REMISSION, morphology (morphologic abnormality), Plasma-Cell, Plasma-Cell Myeloma, myeloma - multiplePlasma-Cell Myelomas, Plasma-cell myeloma, Disease, Myelomas, Immune Systems, PLATEST, determination, Myeloma, Multiple myeloma (disorder), Kahler's disease, postnatal development, Cell Myelomas, growth and development, Myeloma Multiple, Foundation, Myeloma-Multiples, Myeloma-Multiple, Client, Multiple Myeloma, MM, Al amyloidosis, multiple myeloma, development, Kahler, Multiple Myelomas, sensitive, [M]Plasma cell myeloma, Systems, chemical analysis, Myelomatoses, NOS, Myelomatosis, MULT MYELM W/O REMISSION, sensitivity, morphology (morphologic abnormality), Plasma-Cell, Plasma-Cell Myeloma, Plasmacytic myeloma, systemic, Plasma, amyloidosis, no ICD-O subtype (morphologic abnormality)., Multiple myeloma, FOCUS, growth pattern, non-developmental growth, System, Plasma Cell Myelomas, postnatal growth, Specificity, myeloma, Kahler Disease, Estimated, Multiple myeloma without mention of remission, allergic reaction, Multiple, Immune, no ICD-O subtype, Cell Myeloma, multiple, Plasma Cell Myeloma, Specificity and Sensitivity, Patient, no ICD-O subtype (morphologic abnormality), Clients, Sensitivity, assay, Multiple myeloma (clinical), Plasma Cell, growth, Platelets, myeloma - multipleextent, Sectors, Public Sectors, Immune Systems, Procedures, determination, Multiple myeloma (disorder), Kahler's disease, ceramides, postnatal development, Cell Myelomas, number, growth and development, Copyrights, Foundation, Myeloma-Multiples, Myeloma-Multiple, presence, Multiple Myelomas, Techniques, Caucasian, Abc8, Method, sensitive, [M]Plasma cell myeloma, Myelomatoses, Studies, CER, Cer, Public Enterprise, Enterprises, Technique, sensitivity, nessy, Plasmacytic myeloma, systemic, amyloidosis, Multiple myeloma, Occidental, FOCUS, Precerebellin, Plasma Cell Myelomas, Brain protein D3, Public Domains, myeloma, procedures, Estimated, Public Enterprises, Study, allergic reaction, Abstract, Immune, Cell Myeloma, Methodological Studies, no ICD-O subtype (morphologic abnormality), Clients, Sensitivity, Enterprise, Plasma Cell, myeloma - multiple, Plasma-Cell Myelomas, Plasma-cell myeloma, Disease, Papers, Myelomas, PLATEST, AW413978, completeness, Myeloma, Cerebellin, white, LPSAT, Myeloma Multiple, Procedure, wood, Client, Multiple Myeloma, MM, Al amyloidosis, multiple myeloma, development, Kahler, count in organism, OACT5, Public, Public Domain, European, N-acylated sphingoid, Systems, chemical analysis, Domains, NOS, Myelomatosis, techniques, Woods, MULT MYELM W/O REMISSION, morphology (morphologic abnormality), Caucasoid, Domain, Plasma-Cell, Plasma-Cell Myeloma, Data Base, Caucasians, Plasma, growth pattern, non-developmental growth, System, a ceramide, postnatal growth, GRO:0005352, Specificity, Kahler Disease, Methodological, Methodological Study, Multiple myeloma without mention of remission, des-Ser1-cerebellin, Multiple, MBOAT5, LPCAT, Sector, no ICD-O subtype, multiple, Plasma Cell Myeloma, Specificity and Sensitivity, Patient, Whites, 2018, White, Public., assay, Multiple myeloma (clinical), C3F, [des-Ser1]-cerebellin, growth, LPLAT 5, Platelets, methodologyPlasma-Cell Myelomas, Plasma-cell myeloma, Disease, Malignant Neoplasm, Myelomas, Procedures, Myeloma, Multiple myeloma (disorder), Neoplasms, Kahler's disease, Cell Myelomas, Benign Neoplasm, Myeloma Multiple, Procedure, Tumor, Malignant, Myeloma-Multiples, Myeloma-Multiple, Multiple Myeloma, MM, Al amyloidosis, multiple myeloma, Techniques, Kahler, Multiple Myelomas, Benign, Method, [M]Plasma cell myeloma, Studies, Neoplasm, Myelomatoses, NOS, Myelomatosis, techniques, Technique, MULT MYELM W/O REMISSION, morphology (morphologic abnormality), Plasma-Cell, Plasma-Cell Myeloma, Plasmacytic myeloma, systemic, Plasma, amyloidosis, no ICD-O subtype (morphologic abnormality)., Multiple myeloma, Malignancy, Plasma Cell Myelomas, myeloma, Benign Neoplasms, Kahler Disease, Methodological, procedures, Cancers, Methodological Study, Malignant Neoplasms, Multiple myeloma without mention of remission, Study, Neoplasias, Multiple, no ICD-O subtype, Cell Myeloma, Methodological Studies, multiple, Plasma Cell Myeloma, Malignancies, Multiple myeloma (clinical), other neoplasm, Plasma Cell, Neoplasia, myeloma - multiple, methodology, Cancer, TumorsfalseGallaher2018 - Tumor–Immune dynamics in multiple myeloma The paper describes a model on the key components for tumor–immune dynamics in multiple myeloma. Created by COPASI 4.25 (Build 207) This model is described in the article: Methods for determining key components in a mathematical model for tumor–immune dynamics in multiple myeloma Jill Gallaher, Kamila Larripa, Marissa Renardy, Blerta Shtylla, Nessy Tania, Diana White, Karen Wood, Li Zhu, Chaitali Passey, Michael Robbins, Natalie Bezman, Suresh Shelat, Hearn Jay Choo, Helen Moore Journal of Theoretical Biology 458 (2018) 31–46 Abstract: In this work, we analyze a mathematical model we introduced previously for the dynamics of multiple myeloma and the immune system. We focus on four main aspects: (1) obtaining and justifying ranges and values for all parameters in the model; (2) determining a subset of parameters to which the model is most sensitive; (3) determining which parameters in this subset can be uniquely estimated given cer- tain types of data; and (4) exploring the model numerically. Using global sensitivity analysis techniques, we found that the model is most sensitive to certain growth, loss, and efficacy parameters. This anal- ysis provides the foundation for a future application of the model: prediction of optimal combination regimens in patients with multiple myeloma. This model is hosted on BioModels Database and identified by: MODEL1907050001 To cite BioModels Database, please use: BioModels Database: An enhanced, curated and annotated resource for published quantitative kinetic models . To the extent possible under law, all copyright and related or neighbouring rights to this encoded model have been dedicated to the public domain worldwide. Please refer to CC0 Public Domain Dedication for more information. 2024-08-222024-09-022019-07-05BIOMD0000000743SBO:0000179SBO:0000610SBO:0000661SBO:000039330172689C94498C17788C39687C12536C78829C60693C48228C18104C18103BIOMD0000000743MODEL1907050001GO:0002418GO:0035742GO:0008219GO:0002324GO:0002311CL:0000794CL:0000824CL:00008159606000137810.1016/j.jtbi.2018.08.037